Європейський Союз - естонська - EMA (European Medicines Agency)

scipharm sàrl - treprostinil naatrium - hüpertensioon, kopsuvähk - antitrombootilised ained - treatment of adult patients with who functional class (fc) iii or iv and:inoperable chronic thromboembolic pulmonary hypertension (cteph), orpersistent or recurrent cteph after surgical treatmentto improve exercise capacity.

Європейський Союз - естонська - EMA (European Medicines Agency)

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - preparaadid haavade ja haavandite raviks - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Естонія - естонська - Ravimiamet

aop orphan pharmaceuticals gmbh - esmolool - süstelahus - 10mg 1ml 10ml 5tk

Естонія - естонська - Ravimiamet

swedish orphan biovitrum ab - pegtsetakoplaan - infusioonilahus - 1080mg 1tk

Естонія - естонська - Ravimiamet

glaxosmithkline dungarvan limited - paratsetamool+pseudoefedriin+dekstrometorfaan - suukaudse lahuse pulber - 1000mg+60mg+30mg 10tk; 1000mg+60mg+30mg 6tk

Естонія - естонська - Ravimiamet

pharmaestica manufacturing oÜ - paratsetamool+dekstrometorfaan - kihisev tablett - 300mg+7,5mg 10tk; 300mg+7,5mg 20tk

Естонія - естонська - Ravimiamet

vifor france - dekstriferroon - süste-/infusioonidispersioon - 50mg 1ml 10ml 1tk; 50mg 1ml 10ml 2tk; 50mg 1ml 10ml 5tk; 50mg 1ml 2ml 2tk; 50mg 1ml 2ml 5tk

Європейський Союз - естонська - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukeemia, müelogeenne, krooniline, bcr-abl positiivne - antineoplastilised ained - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Європейський Союз - естонська - EMA (European Medicines Agency)

ferrer internacional s.a. - loksapiin - schizophrenia; bipolar disorder - närvisüsteem - adasuve on näidustatud kiire kontrolli kerge kuni mõõduka agitatsioon täiskasvanud patsientidel skisofreenia või bipolaarne häire. patsiendid peavad saama regulaarse ravi kohe pärast ägeda agitatsiooni sümptomite kontrollimist.

Європейський Союз - естонська - EMA (European Medicines Agency)

bayer ag - riociguat - hüpertensioon, kopsuvähk - antihüpertensiivsed ravimid kopsuarteri hüpertensioonile - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektiivsust on näidatud pah elanikkonnale, sh aetiologies idiopaatiline või pärilik pah või pah seotud sidekoe haigus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.